Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
huRH105-DGN549
- Development stage
- Preclinical
- Lead developer
- ImmunoGen
- Modality
- Small Molecules, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
huRH105-DGN549 is an investigational **anti-endoglin antibody-drug conjugate** developed by ImmunoGen for tumor-vasculature targeting. It combines huRH105, a humanized monoclonal antibody that binds endoglin, with DGN549, an indolinobenzodiazepine DNA-alkylating payload. The conjugate was prepared through lysine-directed antibody conjugation and showed endoglin-specific cytotoxicity in endothelial cells plus modest antitumor activity and therapeutic indices in rat xenograft studies. No INN, marketed product, or human clinical development record was identified. ([aacrjournals.org](https://aacrjournals.org/cancerres/article/78/13_Supplement/2900/627388/Abstract-2900-Evaluation-of-endoglin-CD105-as-a))
- Other names
- huRH105 + DGN549anti-endoglin-DGN549 ADCanti-endoglin-DGN-549 ADCanti-endoglin-DGN 549 ADC
02
Targets
DNAENG (Integrin Beta 6)
Beyond the preview
Go deeper on huRH105-DGN549.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on huRH105-DGN549.